Videos

Phase III ROSELLA data shows relacorilant plus nab-paclitaxel improves OS in platinum-resistant ovarian cancer with a manageable safety profile.

Oncology nurses play a vital role in managing cognitive and metabolic toxicities during long-term lorlatinib therapy for ALK+ NSCLC.

ASCO 2026: Dr. Shubham Pant discusses managing the unique side effect profile of daraxonrasib, a new standard of care for metastatic pancreatic cancer.

Dr. Emily Podany explains how oncology nurses can screen for food insecurity and provide evidence-based solutions to improve patient outcomes.

Dr. Paolo Tarantino highlights the need for drug-specific prophylaxis to manage toxicities like ILD and neutropenia in patients receiving ADCs.

Maurie Markman, MD, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, CAR-T in solid tumors, and the decision support gap costing patients.

A DNP-led RESET program explored ways to improve oncology nurse retention by addressing burnout, resilience and grief through education and support.

New research identifies a significant link between immune checkpoint inhibitors and peripheral artery disease, prompting a need for nurse monitoring.

MD Anderson’s trial uses psilocybin to help oncology patients overcome anxiety and depression during maintenance therapy.

Dr. Michael Wong of Roswell Park explains why melanoma survivors must prioritize skin barrier protection over tanning to prevent further UV injury.

Thomas W. Flaig, MD, discusses the 2026 NCCN Guidelines updates for bladder cancer, highlighting the role of enfortumab vedotin, pembrolizumab, and the shift toward neoadjuvant ADC therapy.

Sandy Srinivas, MD, of Stanford Cancer Center, discusses the critical role of patient selection, chemo-fitness, and managing comorbidities when selecting ARPI doublets for older patients with prostate cancer.

Angela Thomas, MSN, APRN, AGPCNP-C, ACHPN, of Texas Oncology, discusses how practitioners can incorporate palliative care techniques into their daily practice.

Anurag K. Agrawal, MD, of the American Cancer Society, discusses global oncology nursing challenges, including high patient ratios, hierarchy, and chemo safety.

Molly Williams, DNP, AGACNP-BC, ACHPN, discusses gaps in oncology through a palliative care lens, focusing on symptom burden, fatigue, and essential support for caregivers.

Lillian Rodich, PA-C, MPH, stressed that nurses can take advantage of accessible and local integrative medicine resources to treat patients with cancer.

Patricia Jakel, MN, RN, AOCN, shares how personal and professional experience impact her view on testing even beyond what is recommended.

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger age groups with mccRCC.

With the addition of pembrolizumab to standard androgen deprivation therapy and radiation, immune-related adverse events are more likely.

David C. Leopold, MD, explains how evidence-based integrative therapies like acupuncture and nutrition improve oncology patient outcomes and compliance.

In a clip from the latest Onc Nurse on Call episode, social worker Kelly Grosklags explains that emotions strengthen the connection between patient and clinician in oncology.

Investigator Elizabeth Lee, MD, discusses efficacy and safety data for rinatabart sesutecan in patients with endometrial cancer.

Elizabeth Lee, MD, shares that rinatabart sesutecan’s mechanism of action may allow more patients with advanced endometrial cancer to receive effective treatment.

Transportation is a key accessibility issue for patients with HR-positive metastatic breast cancer receiving CDK4/6 inhibitors at community clinics.

Emily Coiro, MSN, AGACNP-BC, BMTCN; and Julie Zgola, BSN, RN, who work in stem cell transplantation, were matched with patients in need of a transplant.

Kennon McCollum, DNP, explains how multiday ES-SCLC chemotherapy regimens heighten myelosuppression risk and drive dose delays.

Germline and somatic testing can inform treatment and family risk up front, but NGS is often held for recurrence, explained Courtney R. Arn, APRN-CNP.

Gabriel Schwartz, MSN, NP, explains how mechanisms of action determine the safety of systemic treatments in metastatic colorectal cancer post chemotherapy.